Compugen Ltd (CGEN) Actualités

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors

Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies

Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with...

Compugen Reports Third Quarter 2024 Results

Compugen Reports Third Quarter 2024 Results PR Newswire HOLON, Israel, Nov. 12, 2024 Clinical data presented at SITC 2024 demonstrated COM701...

Compugen to Participate in Stifel 2024 Healthcare Conference

Compugen to Participate in Stifel 2024 Healthcare Conference PR Newswire HOLON, Israel, Nov. 11, 2024 HOLON, Israel, Nov. 11, 2024 /PRNewswire/...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024

Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant...

Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 PR Newswire HOLON, Israel, Oct. 29, 2024 HOLON, Israel...

Compugen to Present New Clinical Data at SITC 2024

Compugen to Present New Clinical Data at SITC 2024 PR Newswire HOLON, Israel, Oct. 7, 2024 HOLON, Israel, Oct. 7, 2024 /PRNewswire/ -- Compugen...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Compugen to Present at Single Cell Genomics 2024 Conference

Compugen to Present at Single Cell Genomics 2024 Conference PR Newswire HOLON, Israel, Sept. 9, 2024 HOLON, Israel, Sept. 9, 2024 /PRNewswire/...

Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference PR Newswire HOLON, Israel, Aug. 29, 2024 HOLON, Israel, Aug...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Compugen Reports Second Quarter 2024 Results

Compugen Reports Second Quarter 2024 Results PR Newswire HOLON, Israel, Aug. 6, 2024 FDA clearance of COM503 IND in July 2024 triggered a $30...